Biogen entered a license agreement with Vanqua Bio, paying $70M upfront for exclusive worldwide rights to a preclinical oral C5aR1 antagonist. The deal includes up to $990M in potential milestone payments, signaling a major investment in early-stage pipeline development and creating needs for clinical trial support, manufacturing scale-up, and regulatory strategy services.
Filing excerpt
In October 2025 we entered into a license agreement with Vanqua granting us exclusive worldwide rights to further develop, manufacture and commercialize Vanqua's preclinical oral C5aR1 antagonist compound.
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
Regions named
Vendors named
sec-10kjointVentureGet every 10-K signal for Biogen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/73aa7ffd-49f8-4e60-b9b1-703697950ff2 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.
{
"signal_id": "73aa7ffd-49f8-4e60-b9b1-703697950ff2",
"signal_type": "sec-10k",
"signal_subtype": "jointVenture",
"detected_at": "2026-02-10T07:50:47.777+00:00",
"company": {
"name": "Biogen",
"domain": "biogen.com"
},
"data": {
"detail": "Biogen entered a license agreement with Vanqua Bio, paying $70M upfront for exclusive worldwide rights to a preclinical oral C5aR1 antagonist. The deal includes up to $990M in potential milestone payments, signaling a major investment in early-stage pipeline development and creating needs for clinical trial support, manufacturing scale-up, and regulatory strategy services.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Upfront payment to Vanqua Bio for license agreement.",
"dollar_millions": 70
},
"summary": "Biogen pays Vanqua Bio $70M upfront for rights to preclinical oral compound",
"excerpts": "In October 2025 we entered into a license agreement with Vanqua granting us exclusive worldwide rights to further develop, manufacture and commercialize Vanqua's preclinical oral C5aR1 antagonist compound.",
"relevance": 0.7,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm",
"filing_date": "2026-02-06",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "New entity needs",
"signal_category": "strategic",
"regions_mentioned": [
"worldwide"
],
"vendors_mentioned": [
"Vanqua Bio, Inc."
]
}
}
curl https://signals.autobound.ai/v1/signals/73aa7ffd-49f8-4e60-b9b1-703697950ff2 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.